VTGN icon

VistaGen Therapeutics

2.00 USD
-0.06
2.91%
At close Jun 20, 4:00 PM EDT
After hours
2.01
+0.01
0.50%
1 day
-2.91%
5 days
-12.66%
1 month
-23.95%
3 months
-27.80%
6 months
-20.00%
Year to date
-39.76%
1 year
-37.89%
5 years
-87.18%
10 years
-98.38%
 

About: Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Employees: 57

0
Funds holding %
of 7,302 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

625% more call options, than puts

Call options by funds: $29K | Put options by funds: $4K

0.51% less ownership

Funds ownership: 55.75% [Q4 2024] → 55.24% (-0.51%) [Q1 2025]

9% less funds holding

Funds holding: 54 [Q4 2024] → 49 (-5) [Q1 2025]

13% less capital invested

Capital invested by funds: $44.9M [Q4 2024] → $39M (-$5.83M) [Q1 2025]

40% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 20

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Research analyst outlook

We haven’t received any recent analyst ratings for VTGN.

Financial journalist opinion

Based on 6 articles about VTGN published over the past 30 days

Neutral
Seeking Alpha
4 days ago
Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2025 Earnings Conference Call June 17, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Mark Adrian McPartland - Senior Vice President of Investor Relations Shawn K. Singh - President, CEO & Director Conference Call Participants Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Lin Tsai - Jefferies LLC, Research Division Myles Robert Minter - William Blair & Company L.L.C.
Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript
Neutral
Business Wire
4 days ago
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corporate update. “This was a defining year for Vistagen, marked by significant progress in our registration-directed PALISADE program for fa.
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
Neutral
Business Wire
1 week ago
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Tuesday, June 17, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 ended March 31, 2025, and provide a corporate updat.
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
Neutral
Business Wire
2 weeks ago
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today provides an update on the timeline for the ongoing clinical trials in its U.S. registration-directed PALISADE Phase 3 Program evaluating fasedienol for acute treatment of social anxiety disorder (SAD). The Company's PALISADE-.
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
Neutral
Business Wire
3 weeks ago
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at Jefferies 2025 Global Life Sciences Conference in New York. Vistagen's President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat on Thursday, June 5, at 11:40 a.m. Ea.
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
Neutral
Business Wire
4 weeks ago
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the American Society of Clinical Psychopharmacology (ASCP) Conference in Scottsdale, Arizona from May 27-30, 2025. The Company's poster presentations will explore the age of onset of social anxiety dis.
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
Neutral
Business Wire
2 months ago
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented new data on social anxiety disorder (SAD) at the 2025 Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada. The Company's poster presentations examined the age of onset of SAD in participants in.
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
Neutral
Business Wire
3 months ago
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada from April 3 to 5, 2025. The Company's poster presentations will explore the age of onset of social anxiety diso.
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
Neutral
Business Wire
3 months ago
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that management will participate in Stifel's 2025 Virtual CNS Forum. Vistagen's President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation on Tuesday, March 18, 2025, at 12 p.m.
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
Neutral
Business Wire
3 months ago
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present at the 45th Annual TD Cowen Healthcare Conference. Vistagen's President and Chief Executive Officer, Shawn Singh, will present a corporate overview on Monday, March 3, 2025, at 2:30 p.m. Eastern Time. A webcast will be acce.
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
Charts implemented using Lightweight Charts™